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Summary: Purpose: To describe the effects of vagus nerve
stimulation (VNS) on sleep-related breathing in a sample of 16
epilepsy patients.
Methods: Sixteen adults with medically refractory epilepsy
(nine men, seven women, ages 21–58 years) underwent base-
line polysomnograms (PSGs). Three months after VNS therapy
was initiated, PSGs were repeated. In addition, patient 7 had a
study with esophageal pressure monitoring, and patient 1 had a
continuous positive airway pressure (CPAP) trial.
Results: Baseline PSGs: One of 16 patients had an apnea–
hypopnea index (AHI) >5 (6.8). Treatment PSGs: Five of 16
patients had treatment AHIs >5. Respiratory events were more
frequent during periods with VNS activation (on-time) than with-
out VNS activation (off-time; p = 0.016). Follow-up studies:
Esophageal pressure monitoring in patient 7 showed crescen-
dos in esophageal pressure during VNS activation, supporting
an obstructive pattern. The CPAP trial of patient 1 showed that
all respiratory events were associated with VNS stimulation at
low CPAP levels. They were resolved at higher CPAP levels.
Conclusions: Treatment with VNS affects respiration during
sleep and should be used with care, particularly in patients with
preexisting obstructive sleep apnea. The AHI after VNS treat-
ment remained <5 in the majority of patients and was only mildly
elevated (<12) in five patients. In one patient, CPAP resolved
VNS-related respiratory events. Key Words: Epilepsy—Vagus
nerve stimulator—Obstructive sleep apnea.
Vagus nerve stimulation (VNS), delivered by a surgi-
cally implanted nerve stimulator (Cyberonics, Houston,
TX, U.S.A.), has proven effective in treating medically re-
fractory epilepsy. Although the exact mechanism by which
VNS reduces seizure frequency is unknown, it is believed
to modulate electrical stimuli to the nucleus tractus solitar-
ius and the brainstem reticular formation. In this way, VNS
may interrupt the synchronous electrical activity charac-
teristic of seizures (1). Common side effects include la-
ryngeal irritation, hoarseness, and dyspnea.
We previously reported in a pilot study of four pa-
tients that VNS is associated with decreased respiratory
airflow and effort during sleep (2). Others have confirmed
our observations. One group reviewed polysomnograms
(PSGs) of six patients with VNS and reported VNS-related
tachypnea in all six. They also reported VNS-related apnea
in two PSGs (3). Another group, which reported on seven
patients treated with VNS, found more events of increased
upper airway resistance during VNS activation (4). A third
group found mild respiratory impairment during sleep as-
Accepted March 1, 2003.
Address correspondence and reprint requests to Dr. B.A. Malow at
Department of Neurology, Vanderbilt University Medical Center, 2100
Pierce Avenue, 320 MCS, Nashville, TN 37212-3375, U.S.A. E-mail:
beth.malow@vanderbilt.edu
sociated with VNS activation in four children treated with
VNS (5). We now extend our findings to include PSGs of
16 patients treated with VNS. We also report on follow-up
PSGs with esophageal pressure monitoring (Pes) and con-
tinuous positive airway pressure (CPAP) therapy to bet-




This protocol was approved by the University of
Michigan Institutional Review Board, and informed con-
sent was obtained. Patients were recruited from patients
18 years or older with medically refractory epilepsy who
underwent evaluation for placement of the VNS device
in the University of Michigan Epilepsy Clinic between
January 1999 and March 2000. All patients had complex
partial seizures with or without secondary generalization,
except for subject 5, who had juvenile myoclonic epilepsy.
Two patients eligible for the protocol chose not to partici-
pate. One subject who underwent a baseline PSG did not
undergo a treatment PSG because he was never implanted
with the device because of insurance disapproval. Sixteen
adults (nine men, seven women), ranging in age from 21 to
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58 years (mean age, 33.6 ± 11.1, standard deviation), un-
derwent baseline PSGs and Multiple Sleep Latency Tests
(MSLTs) according to standard procedure in the Michael
S. Aldrich Sleep Disorders Laboratory at the University of
Michigan. Three months after VNS was initiated, PSGs
and MSLTs were repeated. Patients were asked to keep
accurate seizure logs during the period between baseline
and treatment PSGs. The primary objective of this proto-
col was to assess the effect of VNS on daytime sleepiness,
results that have been reported previously (6). The effects
of VNS on respiration during sleep (decreased airflow and
effort) were unanticipated findings in the first four patients
recorded, and were the subject of an expedited publication
(2). Respiratory data from these four previously presented
patients (patients 1, 7, 8, and 10) are included in this report
for completeness.
Patients were excluded if they had cognitive impairment
severe enough to interfere with their ability to provide
informed consent or to participate in the study. Because
sleep disorders can result in daytime sleepiness, patients
reporting a history of any sleep disorder other than treated
obstructive sleep apnea were excluded from the proto-
col. Referring physicians were asked to keep patients on
stable doses of antiepileptic medications (AEDs) during
the 3 months between baseline and treatment studies, un-
less changes were necessary because of escalating seizure
frequency or medication toxicity. (See Table 1 for medi-
TABLE 1. Patient characteristics
Patient no.— Baseline Sz freq. after 3 mo B-AHI T-AHI B-min. T-min. Stimulus
age/gender sz/mo VNS therapy (REM AHI) (REM AHI) O2 O2 intensity AEDs in mg/day
1—35/m 4 Reduced 100% 4.0 (14) 11.3a (15.7) 91 84 1.0 LTG, 600; PHT, 400; CZP, 1.0
2—27m 6–10 Unchanged 2.0 (1.5) 10.1a(8.6) 90 90 1.25 PHT, 200; FBM, 5,400
3—46/fb >20 Reduced 45% 0.9 (4.4) 9.9a (2.3) 93 90 0.75 CBZ, 1,400; LTG, 450
4—57/f 6–10 Unchanged 4.9 (0) 8.2a (20.6) 89 88 1.25 PHT, 400; LTG, 200; levothyroxine, 0.2
5—34/m 5 Reduced 20% 1.4 (2) 5.9a (1.8) 93 93 0.75 PHT, 400; TGB, 48
6—33/m 4–5 Reduced 100% 1.3 (0.9) 2.9 ( 9.5) 96 94 1.75 PHT, 325; sertraline, 100
7—58/f 3 Unchanged 6.8a (22) 4.5 (7.3) 87 81 2.0 PHT, 300; TGB, 28
8—20/m 5 Reduced 40% 0.6 (2.1) 2.6 (4.3) 90 91 1.5 CBZ, 3,200; LTG, 700
9—26/ml 11–20 Unchanged 1.1 (3.1) 2.4 (2.1) 94 88 1.0 LEV,c 3,000; LTGc, 350; risperidone, 5
10—31/f 6–10 Unchanged 0.8 (8.8) 2.1 (0) 90 91 1.75 PHT, 425; TPM, 500
11—27/m 60 Reduced 50% 1.4 (17.8) 1.8 (2.1) 94 88 1.5 CBZ, 1,000; VPA, 3,000; PB, 100;
sertraline, 200
12—31/m 6–10 Reduced 50% 0.3 (0.5) 1.5 (0.7) 94 95 0.75 PHT, 400; TPM, 100
13—22/f >20 Unchanged 0.3 (0) 1.3 (2.6) 95 95 1.25 CBZ, 1,600; TPM, 300
14—25/f 6–10 Unchanged 3.0 (15) 1.3 (4) 93 88 2.75 VPA, 2,250c; CBZ, 1,400; sertraline, 50
15—29/m >20 Unchanged 1.1 (1.4) 1.0 (4.2) 94 90 1.25 LTG, 500; VPA, 1,125; PHT, 430;
LZP, 6; GBP, 4,800
16—36/f >20 Unchanged 0 (0) 0.1 (0) 94 94 0.75 CBZ, 2,000c; PB, 120;
levothyroxine, 0.075
All patients were stimulated with 250- or 500-µs pulse width and 30-Hz frequency.
AHI, apnea–hypopnea index; B, baseline; T, treatment; min. O2, minimum oxygen saturation; AED, antiepileptic drug; CBZ, carbamazepine; PB,
phenobarbital; PHT, phenytoin; TPM, topiramate; TGB, tiagabine; LTG, lamotrigine; CZP, clonazepam; LEV, levetiracetam; FBM, felbamate; VPA,
valproic acid; LZP, lorazepam; GBP, gabapentin.
a Clinically significant AHI (>5).
b VNS set at a more rapid cycling rate (30-s stimulation every 3 min).
c Patient 9: LEV increased to 3,500, and LTG increased to 600; Patient 14, VPA decreased to 2,000; Patient 16, CBZ increased to 2,400 between
baseline and treatment studies.
cation changes that occurred between baseline and VNS
treatment studies in patients 9, 11, and 14).
Vagus nerve stimulator device
The Vagus Nerve Stimulator device (Cyberonics,
Houston, TX, U.S.A.) consists of a spiral bipolar elec-
trode wrapped around the left vagus nerve and connected
to a pulse generator (1). The generator is implanted in
the infraclavicular region on the left side. Intraoperative
impedance testing is performed to ensure electrical con-
tinuity of the VNS system. The device is activated at the
patient’s first postoperative outpatient visit with a wand
placed over the generator.
In each patient, the parameters of the electrical output
were programmed on postsurgical activation of the device.
Electrical stimulus intensities were set according to estab-
lished guidelines regarding seizure frequency and patient
tolerance (7). The stimulus intensities ranged among pa-
tients from 0.75 to 2.75 mA, at 30-Hz frequency and 250
or 500 µs pulse width. Fifteen of the 16 patients received
stimulation for 30 s, with intervening 5-min off-periods.
In patient 3, the VNS device was activated for 30 s, with
intervening 3-min off-periods (more rapid cycling). Each
patient’s VNS device was programmed at the postoper-
ative visit, and no changes in the VNS parameters were
made during the 3-month period between baseline and
treatment study.
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Polysomnography
Polysomnograms were recorded on 32-channel com-
puterized EEG systems (Grass Telefactor Corp., West
Conshohocken, PA, U.S.A.) and included EEG, elec-
trooculogram, submental electromyogram (EMG), nasal–
oral airflow, thoracic and abdominal effort as measured
by belts containing piezo crystals, pulse oximetry, and
anterior tibialis EMG. EEG was recorded with a 0.3-Hz
low-frequency filter and 70-Hz high-frequency filter. The
sampling rate used was 200 Hz. For VNS treatment
PSGs, a surface electrode was placed over the site of the
VNS lead and referenced to a second surface electrode
placed laterally to record when the VNS was activated
(“activation-time”).
Studies were staged and scored for respiratory events by
the first author, a registered technologist (M.M.), blinded
to the VNS signal. The senior author (B.A.M.) confirmed
accuracy of scoring. Respiratory analysis was done ac-
cording to the protocol of our laboratory. According to
these standards, an obstructive apnea is defined as an 80%
decrease in airflow from baseline amplitude for ≥10 s. A
hypopnea is defined as a 10-s, 50–80% decrease in air-
flow or effort of baseline amplitude associated with an
EEG arousal (8), or an oxygen desaturation of ≥4%. In
our laboratory, obstructive versus central hypopneas are
not distinguished. However, if effort is preserved during a
hypopnea, we tend to characterize it as obstructive.
The apnea–hypopnea indices (AHIs) for each study
were calculated by dividing the number of apneas and
hypopneas per hour of sleep. An AHI of ≥5 was cho-
sen to define clinically significant obstructive sleep apnea
(OSA) (9). For patients with clinically significant OSA on
studies with VNS, separate AHIs were calculated for VNS
activation and nonactivation periods of sleep to relate res-
piratory events to VNS activations. Activation AHIs were
calculated by using the number of respiratory events per
hour that occurred during VNS activation. Nonactivation
AHIs were calculated in the same manner by using res-
piratory events and sleep time that occurred during VNS
off-time. Calculating AHIs separately for VNS activation
and nonactivation periods compensated for differences in
overall AHIs between baseline and treatment studies that
may have been owing to night-to-night variability of sleep
and of apnea in the same patient. VNS activation and non-
activation occurred in an alternating pattern periodically
throughout all stages and positions of sleep. We calcu-
lated separate AHIs for stimulus on and off periods only
for those patients with clinically significant AHIs, because
we thought this to be the most meaningful group to study.
Follow-up studies
Two patients returned to the sleep laboratory for fur-
ther testing for clinical indications after completing the
protocol. Patient 1 (treatment AHI, 11.3) underwent a
CPAP titration in the laboratory. Patient 7 underwent one
PSG with esophageal pressure monitoring (Pes) and nasal
pressure in addition to the standard nasal–oral thermis-
tor. This follow-up PSG was performed because several
arousals were associated with snoring, which indicated
possible upper airway resistance syndrome on the treat-
ment PSG. This clinical symptom was not present on the
baseline PSG for this patient. Therefore, more information
was necessary to diagnose her sleep-disordered breathing
syndrome.
Statistical analysis
Statistical tests were performed by using the SPSS sta-
tistical analysis package (SPSS Inc., Chicago, IL, U.S.A.).
For all statistical tests, the level of significance was set at
α = 0.05. Two-sample paired t tests were used to deter-
mine differences in AHI between the baseline and treat-
ment studies and also between VNS activation periods and
nonactivation periods in treatment studies. Two-sample
independent t tests were used to examine whether age or
body mass index (BMI) differed between patients with
AHIs <5 and those with AHIs ≥5. χ2 tests were used to
examine whether gender differed between patients with
AHIs <5 and those with clinically significant AHIs (≥5).
RESULTS
Baseline sleep studies
Only patient 7 of the 16 had a baseline AHI >5 (6.8;
Table 1). Patient 12, who initially had an AHI of 37, was
treated with CPAP and was entered in the protocol with
an AHI of 0.3.
VNS treatment sleep studies
Fourteen of the 16 patients had increased AHIs on treat-
ment PSGs. In the 16 patients overall, the treatment AHI
was higher than the baseline AHI (p = 0.008). The respi-
ratory patterns in all 16 patients were identical to those re-
ported in our prior publication and consisted of consistent
decreases in airflow with diminished but relatively pre-
served effort, often associated with tachypnea, which oc-
curred during VNS activation. They sometimes met scor-
ing criteria for apneas or hypopneas. We did not see any
central apneas in association with VNS.
AHIs increased to clinically significant levels (AHI >
5) in five patients. Patients 1 and 2 had ≥10 events per
hour. We analyzed the activation and nonactivation AHIs
in treatment PSGs in those patients with treatment AHIs >
5 and found a higher activation AHI (p = 0.016; Table 2).
Patient 7, with a 6.8 baseline AHI, had a lower treatment
AHI of 4.5, which was not owing to decreases in rapid eye
movement (REM) sleep, supine, or REM–supine sleep and
may reflect night-to-night variability.
Patients with an elevated AHI (>5) did not differ in
age, gender, or BMI (p > 0.10). The effects of VNS ther-
apy on seizure control in patients with an elevated AHI
were comparable to those without an elevated AHI. Those
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TABLE 2. Separate AHI on VNS treatment PSGs for patients
with clinically significant AHIs
Patient no. AHI Activation AHI Nonactivation AHI
1 11.3 26.2 6.9
2 10.1 11.9 7.6
3 9.9 20.2 6.9
4 8.2 16.2 3.1
5 5.9 10.7 5.2
7-np/Pes study 12.9 40.9 5.9
Activation AHI was significantly higher than nonactivation AHI (two-
tailed paired t test; p = 0.016).
AHI, apnea–hypopnea index; Activation AHI, AHI for periods when
vagus nerve stimulator (VNS) was activated; Nonactivation AHI, for
periods when VNS was not activated; np, nasal pressure; Pes, esophageal
pressure.
with an elevated AHI had a mean seizure reduction of
33 ± 42%, and those without an elevated AHI had a mean
seizure reduction of 22 ± 34% (p > 0.10). Two of the five
patients with elevated AHIs had evidence of preexisting
sleep apnea. After completion of our study, the caregiver
of patient 1 reported witnessed apneic episodes and snor-
ing. Patient 2 had previously undergone a tonsillectomy
to treat OSA. As mentioned earlier, patient 3’s VNS cy-
cled more rapidly than the others. Therefore, the amount
of VNS activation time during sleep was higher for that
patient than for the others. Other factors associated with
an increased AHI could not be identified in the other two
patients with treatment AHIs >5. Patient 12, who had pre-
existing OSA treated with CPAP, did not have worsening
of his OSA with VNS treatment.
Follow-up sleep studies
Patient 1 had an AHI of 3.8 for the follow-up PSG
with CPAP titration. At lower pressures of CPAP (5 and
FIG. 1. Two-minute epoch of
polysomnography with nasal
pressure, esophageal pressure,
and vagus nerve stimulation (VNS).
Black arrow , VNS activation (on-
time) and corresponding decrease
in nasal pressure and airflow and
EEG arousal from sleep. Open
arrow , crescendo increase (i.e.,
progressive increase over several
breaths) in esophageal pressure
associated with respiratory event.
LOC, left outer canthus; ROC,
right outer canthus; chin, chin
electromyogram; C3-AVG and
C4-AVG, central EEG channels;
O1-AVG and O2-AVG, occipital
EEG channels; LAT, left anterior
tibialis; RAT, right anterior tibialis;
PSN, vagal nerve signal; NPR,
nasal pressure; oral-nasal , oral–
nasal thermistor; thor , thoracic
effort; abd , abdominal effort; PES,
esophageal pressure monitor.
7 cm), all apneas and hypopneas were VNS related and
resembled the patterns previously described in the VNS
treatment sleep studies. The events were resolved at 9 cm
of CPAP pressure. Patient 7’s follow-up study was done
with Pes and nasal pressure. The AHI based on the nasal–
oral thermistor was 12.9. Analysis of this study showed
crescendo patterns in the Pes channel during VNS activa-
tion, supporting an obstructive pattern (Fig. 1). At times, a
lag occurred between the onset of VNS activation and the
PES crescendo seen. Recordings from the nasal pressure
channel also supported an obstructive pattern, as effort
was diminished but observable throughout the events. The
higher AHI for this follow-up study, as compared with the
VNS treatment study, may have been the result of having
nasal pressure monitoring and esophageal pressure moni-
toring, which allowed detection of respiratory events that
did not meet scoring criteria that applied to previous stud-
ies with only the nasal–oral thermistor. This patient was
then offered a CPAP titration but declined CPAP therapy.
DISCUSSION
In this study, we extended our prior observations on the
effects of VNS on sleep-related breathing to a total of 16
patients. In comparing AHIs for baseline and treatment
studies, respiratory events increased to clinically signifi-
cant levels in five (31%) of our 16 patients. To determine
what portion of these AHIs could be attributed to the VNS
activation, we calculated separate AHIs for VNS activa-
tion sleep time and nonactivation sleep time and found that
AHIs were significantly higher during VNS activation.
In all subjects, we observed decreases in airflow and
effort coinciding with VNS activations. The effort was
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generally preserved compared with decreases in airflow,
suggesting that airway patency was compromised. This
compromise in airway patency was further supported by
nasal and esophageal pressure monitoring in one patient
and the resolution of respiratory events during a CPAP
titration study in another patient. The nasal and esophageal
monitoring study showed that airflow decreased and pres-
sure increased, whereas effort was sustained through the
events (Fig. 1). In addition, one patient with preexisting
OSA (patient 12) treated with CPAP showed no worsening
of OSA with VNS treatment.
In our previously published pilot work, we discussed the
various mechanisms whereby VNS may affect respiration
during sleep (2). These include both peripheral effects on
upper airway musculature innervated by the vagus nerve
and more central mechanisms influencing upper airway
patency and respiratory effort. VNS activation of C-fibers,
or other mechanisms related to VNS activation, may ex-
plain the tachypnea associated with respiratory changes
during sleep (3). Of relevance to and consistent with our
work is the recently reported finding that atrial overdrive
pacing reduced obstructive and central apneas in patients
with sinus-node dysfunction and coexisting sleep apnea.
The authors of this report postulated that the reduction in
vagal tone caused by cardiac pacing might exert its benefi-
cial effect on sleep-disordered breathing via a reduction in
vagal tone (10). VNS increases vagal tone, whereas car-
diac pacing reduces vagal tone—these opposing effects
may explain why VNS caused reduced airflow and ef-
fort during sleep, and cardiac pacing ameliorated sleep-
disordered breathing.
The clinical impact of VNS on sleep-related breathing
remains uncertain. In our sample, the effects of VNS on
breathing during sleep are mild in most cases. Seizure
improvements in the five patients with increased AHIs
were similar to those of the other 11 patients, indicating
that in this population, the effects of mild OSA are not
a barrier to seizure improvement. Only two patients of
the 16 had an AHI >10 with VNS (patients 1 and 2),
and both had prior evidence of OSA (although not known
in patient 1 at time of inclusion in our study). Patient 1
was treated with CPAP, and patient 2 received positional
therapy, as the majority of respiratory events occurred in
the supine position. The other three patients with AHIs
>5 were treated with positional therapy, given that the
majority of respiratory events occurred in supine position
in these cases as well. A limitation of our study is that we
were not able to bring these patients back for follow-up
studies to determine whether OSA associated with VNS
activation was improved by the positional therapy.
As this protocol was designed to investigate the effects
of VNS on daytime sleepiness, not sleep-related breathing,
some limitations occurred in our study. One of the limita-
tions is that patients with untreated OSA were excluded;
therefore the effects of VNS on sleep-related breathing
in patients with untreated or unrecognized OSA are un-
known. In addition, only one patient had nasal pressure
and esophageal pressure monitoring. Further controlled
studies of VNS patients with monitoring of nasal pressure,
esophageal pressure, or both are necessary to quantify def-
initely the central or obstructive nature of the effects of
VNS. We observed that crescendos in esophageal pres-
sure were not consistently time-locked to the start of VNS
activation, suggesting that VNS effects on respiration dur-
ing sleep are complex and will require further quantifica-
tion in future studies. We also observed mild elevations in
the nonactivation AHIs, although not to the same extent as
during activation. This may reflect night-to-night variabil-
ity or effects of VNS on upper airway patency, although
this latter possibility must be investigated in follow-up
studies. Finally, AEDs also may affect respiration through
weight gain or changes in upper airway tone (11,12). Such
AED effects may interact with the VNS treatment to af-
fect respiration during sleep. Further studies with larger
numbers of patients will be necessary to address this issue.
As a result of our preliminary report on the effects of
VNS on sleep-related breathing (2), Cyberonics issued a
caution in their product labeling to read ’’Patients with
obstructive sleep apnea (OSA) may have increased apneic
events during stimulation. Cyberonics recommends care
when treating patients with preexisting OSA. Lower stim-
ulating frequencies or prolonging off-time may prevent
exacerbation of OSA.’’ At the University of Michigan,
we now approach the concern of OSA being related to
VNS by taking a careful sleep history, exploring symp-
toms of sleep-related breathing. If OSA is likely, a PSG is
performed, and clinically significant OSA is treated before
VNS is implanted. In addition to minimizing the poten-
tial risk of VNS worsening sleep-disordered breathing,
treating OSA may reduce seizures and improve patient
tolerance of AEDs (13–15). Although the mechanisms
whereby VNS affects sleep-related respiration remain un-
clear and warrant further study, CPAP appears to be an
effective treatment in patients in whom OSA develops
during VNS.
VNS is an effective and useful treatment for epilepsy. Its
effect on sleep-related breathing warrants further investi-
gation and care in treating patients. Further directions for
this work include performance of follow-up PSGs in pa-
tients treated with VNS to determine whether the effects
on sleep-related breathing diminish over time.
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